• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.

    2/11/25 11:08:22 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRNS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    MARINUS PHARMACEUTICALS, INC.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    56854Q200

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    56854Q200


    1Names of Reporting Persons

    Franklin Resources, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    HC, CO


    SCHEDULE 13G

    CUSIP No.
    56854Q200


    1Names of Reporting Persons

    Charles B. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    56854Q200


    1Names of Reporting Persons

    Rupert H. Johnson, Jr.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    MARINUS PHARMACEUTICALS, INC.
    (b)Address of issuer's principal executive offices:

    5 Radnor Corporate Center, Suite 500, 100 Matsonford Rd., Radnor, PA 19087
    Item 2. 
    (a)Name of person filing:

    (i): Franklin Resources, Inc. (ii): Charles B. Johnson (iii): Rupert H. Johnson, Jr.
    (b)Address or principal business office or, if none, residence:

    (i), (ii), (iii): One Franklin Parkway San Mateo, CA 94403-1906
    (c)Citizenship:

    (i) Delaware (ii) and (iii): USA
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    56854Q200
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0.0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Franklin Resources, Inc.: 0 Charles B. Johnson: 0 Rupert H. Johnson, Jr.: 0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    Franklin Resources, Inc.: 0 Charles B. Johnson: 0 Rupert H. Johnson, Jr.: 0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The clients of the Investment Management Subsidiaries, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, the securities reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Attached Exhibit C
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Franklin Resources, Inc.
     
    Signature:/s/Thomas C. Mandia
    Name/Title:Thomas C. Mandia, Assistant Secretary of Franklin Resources, Inc.
    Date:02/11/2025
     
    Charles B. Johnson
     
    Signature:/s/Thomas C. Mandia
    Name/Title:Attorney in Fact for Charles B. Johnson pursuant to Power of Attorney attached to this Schedule 13G
    Date:02/11/2025
     
    Rupert H. Johnson, Jr.
     
    Signature:/s/Thomas C. Mandia
    Name/Title:Attorney in Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney attached to this Schedule 13G
    Date:02/11/2025

    Comments accompanying signature:  LIMITED POWER OF ATTORNEY FOR SECTION 13 AND 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Thomas C. Mandia, Beth McAuley O'Malley, Thomas C. Merchant, Kimberly H. Novotny, Virginia E. Rosas and Navid J. Tofigh each acting individually, as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to: 1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. ("FRI") and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a "Reporting Entity"), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act"); and 2. seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and 3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing. The undersigned acknowledges that: 1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information; 2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable; 3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and 4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act. The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith. This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 11th day of December, 2023. /s/CHARLES B. JOHNSON Signature Charles B. Johnson Print Name LIMITED POWER OF ATTORNEY FOR SECTION 13 AND 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Thomas C. Mandia, Beth McAuley O'Malley, Thomas C. Merchant, Kimberly H. Novotny, Virginia E. Rosas and Navid J. Tofigh each acting individually, as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to: 1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. ("FRI") and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a "Reporting Entity"), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act"); and 2. seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and 3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing. The undersigned acknowledges that: 1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information; 2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable; 3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and 4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act. The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith. This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 11th day of December, 2023. /s/RUPERT H. JOHNSON, JR. Signature Rupert H. Johnson, Jr. Print Name
    Exhibit Information

    Exhibit A: Joint Filing Agreement Exhibit B: Item 4 Ownership Exhibit A: JOINT FILING AGREEMENT In accordance with Rule 13d 1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other of the attached statement on Schedule 13G and to all amendments to such statement and that such statement and all amendments to such statement are made on behalf of each of them. IN WITNESS WHEREOF, the undersigned have executed this agreement on the date of the signing of this filing. Franklin Resources, Inc. Charles B. Johnson Rupert H. Johnson, Jr. By: /s/THOMAS C. MANDIA Assistant Secretary of Franklin Resources, Inc. Attorney in Fact for Charles B. Johnson pursuant to Power of Attorney attached to this Schedule 13G Attorney in Fact for Rupert H. Johnson, Jr. pursuant to Power of attached to this Schedule 13G Exhibit B: Item 4 Ownership The securities reported herein are beneficially owned by one or more open or closed end investment companies or other managed accounts that are investment management clients of investment managers that are direct and indirect subsidiaries (each, an "Investment Management Subsidiary" and, collectively, the "Investment Management Subsidiaries") of Franklin Resources Inc. ("FRI"), including the Investment Management Subsidiaries listed in this Item 4. When an investment management contract (including a sub advisory agreement) delegates to an Investment Management Subsidiary investment discretion or voting power over the securities held in the investment advisory accounts that are subject to that agreement, FRI treats the Investment Management Subsidiary as having sole investment discretion or voting authority, as the case may be, unless the agreement specifies otherwise. Accordingly, each Investment Management Subsidiary reports on Schedule 13G that it has sole investment discretion and voting authority over the securities covered by any such investment management agreement, unless otherwise noted in this Item 4. As a result, for purposes of Rule 13d-3 under the Act, the Investment Management Subsidiaries listed in this Item 4 may be deemed to be the beneficial owners of the securities reported in this Schedule 13G. Beneficial ownership by Investment Management Subsidiaries and other FRI affiliates is being reported in conformity with the guidelines articulated by the SEC staff in Release No. 34-39538 (January 12, 1998) (the "1998 Release") relating to organizations, such as FRI, where related entities exercise voting and investment powers over the securities being reported independently from each other. The voting and investment powers held by each of FRI's affiliates whose ownership of securities is disaggregated from that of FRI in accordance with the 1998 Release ("FRI Disaggregated Affiliates") are exercised independently from FRI and from all other Investment Management Subsidiaries (FRI, its affiliates and the Investment Management Subsidiaries other than FRI Disaggregated Affiliates are collectively, "FRI Aggregated Affiliates"). Furthermore, internal policies and procedures of, on the one hand, FRI Disaggregated Affiliates, and, on the other hand, FRI establish informational barriers that prevent the flow among, on the one hand, FRI Disaggregated Affiliates (including preventing the flow between such entities), and, on the other hand, the FRI Aggregated Affiliates of information that relates to the voting and investment powers over the securities owned by their respective investment management clients. Consequently, FRI Disaggregated Affiliates report the securities over which they hold investment and voting power separately from the FRI Aggregated Affiliates for purposes of Section 13 of the Act. Charles B. Johnson and Rupert H. Johnson, Jr. (the "Principal Shareholders") may each own in excess of 10% of the outstanding common stock of FRI and are the principal stockholders of FRI(see FRI's Proxy Statement-Stock Ownership of Certain Beneficial Owners). FRI and the Principal Shareholders may be deemed to be, for purposes of Rule 13d 3 under the Act, the beneficial owners of securities held by persons and entities for whom or for which FRI subsidiaries provide investment management services. The number of shares that may be deemed to be beneficially owned and the percentage of the class of which such shares are a part are reported in Items 9 and 11 of the cover page for FRI. FRI, the Principal Shareholders and each of the Investment Management Subsidiaries disclaim any pecuniary interest in any of such securities. In addition, the filing of this Schedule 13G on behalf of the Principal Shareholders, FRI and the FRI Aggregated Affiliates, as applicable, should not be construed as an admission that any of them is, and each of them disclaims that it is, the beneficial owner, as defined in Rule 13d-3, of any of the securities reported in this Schedule 13G. FRI, the Principal Shareholders, and each of the Investment Management Subsidiaries believe that they are not a "group" within the meaning of Rule 13d-5 under the Act and that they are not otherwise required to attribute to each other the beneficial ownership of the securities held by any of them or by any persons or entities for whom or for which the Investment Management Subsidiaries provide investment management services.

    Get the next $MRNS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRNS

    DatePrice TargetRatingAnalyst
    9/23/2024$6.00Perform → Outperform
    Oppenheimer
    8/14/2024Buy → Neutral
    Ladenburg Thalmann
    4/16/2024$20.00 → $2.00Outperform → Neutral
    Robert W. Baird
    4/15/2024$24.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    8/11/2023$14.00 → $9.00Outperform → Perform
    Oppenheimer
    1/20/2023$23.00Outperform
    RBC Capital Mkts
    12/20/2021$32.00 → $30.00Outperform
    SVB Leerink
    More analyst ratings

    $MRNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

      Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241230307666/en/ The acquisition complements and further strengthens Immedica's global rare disease business by adding ZTALMY® (ganaxalone) oral suspension, CV, a neuroactive steroid gamma-aminobuty

      12/30/24 7:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

      ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alternatives Marinus continues to support the commercial growth of ZTALMY; further ganaxolone clinical development has been suspended Scheduled to meet with FDA Q4 2024 to discuss a potential path forward for IV ganaxolone in refractory status epilepticus Cost reduction plans implemented with cash runway expected into Q2 2025; cash and cash equivalents of $42.2 million as of September 30, 2024 Marin

      11/12/24 4:00:00 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

      Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than placebo Ganaxolone was generally well-tolerated in TrustTSC with a safety profile consistent with previous clinical trials Cost reduction activities are underway Marinus has engaged Barclays as an advisor to assist with evaluating strategic alternatives Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures as

      10/24/24 8:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

      SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/15/24 10:35:20 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

      SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/14/24 6:39:04 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

      SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      11/14/24 3:04:48 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Marinus Pharmaceuticals upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Marinus Pharmaceuticals from Perform to Outperform and set a new price target of $6.00

      9/23/24 7:37:13 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded Marinus Pharmaceuticals from Buy to Neutral

      8/14/24 7:42:32 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Marinus Pharmaceuticals from Outperform to Neutral and set a new price target of $2.00 from $20.00 previously

      4/16/24 8:12:28 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN AND CEO Braunstein Scott bought $6,526 worth of shares (5,933 units at $1.10) and returned $167,530 worth of shares to the company (304,600 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:11:48 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Leadership Updates

    Live Leadership Updates

    See more
    • DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

      Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

      1/22/24 8:23:00 AM ET
      $DMAC
      $MRNS
      $NKTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D.

      Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors. "Sarah is an accomplished healthcare executive with extensive global clinical development and corporate strategy experience," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "With a track record of successfully advancing programs in various therapeutic areas using diverse modalities, a deep understanding of orphan diseases and over a decade of experience as a hospitalist physician, her unique perspective will be invalu

      5/17/23 4:01:00 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

      Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors. "With over 34 years of diverse commercial operations experience at Merck & Co., we are delighted that Marvin is joining the Marinus Board," said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. "His impressive background launching products across multiple therapeutic categories, including neurology and acute care, will be invaluable in supporting the continued commercial success of ZTALMY® and in preparing for a potential hospital

      4/18/23 7:01:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ezickson Elan returned $5,995 worth of shares to the company (10,900 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:19:58 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Fischer Seth H. Z. returned $8,254 worth of shares to the company (15,007 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:19:21 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF MEDICAL OFFICER Hulihan Joseph returned $39,999 worth of shares to the company (72,725 units at $0.55), closing all direct ownership in the company (SEC Form 4)

      4 - MARINUS PHARMACEUTICALS, INC. (0001267813) (Issuer)

      2/11/25 9:18:26 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    SEC Filings

    See more
    • SEC Form 15-12G filed by Marinus Pharmaceuticals Inc.

      15-12G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)

      2/21/25 8:00:27 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Marinus Pharmaceuticals Inc.

      SCHEDULE 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

      2/14/25 4:00:04 PM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Marinus Pharmaceuticals Inc.

      EFFECT - MARINUS PHARMACEUTICALS, INC. (0001267813) (Filer)

      2/14/25 12:15:08 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRNS
    Financials

    Live finance-specific insights

    See more
    • Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

      ZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35 million Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxolone in tuberous sclerosis complex (TSC) with topline data expected in the first half of Q4 2024 Expanded ZTALMY global footprint with activation of managed access programs for MENA, Russia and Canada with upcoming commercial launches anticipated in Europe and China Succeeded in post-grant review challenge of Ovid Therapeutics' U.S. Patent 11,395,817 for IV ganaxolone in the treatment of status epilept

      8/13/24 7:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports Second Quarter 2024 Financial Results

      Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

      8/6/24 4:01:00 PM ET
      $AGEN
      $AMGN
      $CASI
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

      Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will host a conference call at 8:30 a.m. E.T. on August 13, 2024, to provide a business update and discuss financial results. Tuesday, August 13, 8:30 a.m. E.T. Domestic: (877) 405-1242 International: (201) 389-0852 Webcast Registration: Click Here An archived version of the call will be available approximately two hours after the completion of the event on the Marinus website at ir.marinuspharma.com/e

      7/30/24 8:00:00 AM ET
      $MRNS
      Biotechnology: Pharmaceutical Preparations
      Health Care